Open AccessTargeting transcriptional regulation of SARS-CoV-2 entry factorsACE2andTMPRSS2
Author(s) -
Yuanyuan Qiao,
Xiaoming Wang,
Rahul Mannan,
Sethuramasundaram Pitchiaya,
Yuping Zhang,
Jesse W. Wotring,
Lanbo Xiao,
Dan R. Robinson,
YiMi Wu,
Jean C. Tien,
Xuhong Cao,
Stephanie A. Simko,
Ingrid J. Apel,
Pushpinder Bawa,
Steven Kregel,
Sathiya Pandi Narayanan,
Gregory Raskind,
Stephanie J. Ellison,
Abhijit Parolia,
Sylvia Zelenka-Wang,
Lisa McMurry,
Fengyun Su,
Rui Wang,
Yunhui Cheng,
Andrew Delekta,
Zejie Mei,
Carla D. Pretto,
Shaomeng Wang,
Rohit Mehra,
Jonathan Z. Sexton,
Arul M. Chinnaiyan
Publication year - 2020
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2021450118
Subject(s) - tmprss2 , biology , androgen receptor , receptor , angiotensin converting enzyme 2 , lung , endocrinology , androgen , cancer research , medicine , immunology , prostate cancer , hormone , genetics , covid-19 , cancer , disease , infectious disease (medical specialty)
Significance New therapeutic targets are urgently needed against SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. Results in this study show that targeting the transcriptional regulation of host entry factors TMPRSS2 and ACE2 is a viable treatment strategy to prevent SARS-CoV-2 infection. In particular, inhibitors of androgen receptor (AR) or bromodomain and extraterminal domain (BET) proteins are effective against SARS-CoV-2 infection. AR inhibitors are already approved in the clinic for treatment of prostate cancer and are under investigation in COVID-19 patients; BET inhibitors are also in clinical development for other indications and could be rapidly repurposed for COVID-19.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom